About Regenerative Patch Technologies (RpT)

Regenerative Patch Technologies LLC (RPT) is a California-based biotechnology company focused on the development of stem cell-based implant technology for the treatment of retinal diseases. RPT has developed a bioengineered, composite subretinal implant, termed the California Project to Cure Blindness-Retinal Pigmented Epithelium 1 (CPCB-RPE1), consisting of a polarized monolayer of human embryonic stem cell-derived RPE cells (hESC-RPE) on an ultrathin, synthetic parylene substrate designed to mimic Bruch's membrane. The company has successfully filed an IND on the product and completed enrollment and three-year follow-up of subjects in a Phase 1/2a clinical trial with the advanced form of dry age-related macular degeneration known as geographic atrophy. RPT is actively advancing scientific, manufacturing, and clinical development of the implant and preparing for a Phase 2b clinical trial in patients with geographic atrophy.